Physician profile
John Muratori
NPI 1881788123
$2,726.42
in general payments reported to CMS, 2019-2025
24 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.44 · 2021: $309 · 2022: $595 · 2023: $482 · 2024: $628 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $411.99 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $332.96 | 2023-2025 | |
| Novo Nordisk INC | $209.49 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $189.86 | 2021-2025 | |
| Daiichi Sankyo INC. | $172.75 | 2022-2023 | Injectafer |
| Exact Sciences Corporation | $171.13 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $161.05 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.40 | 2022-2023 | Trulance, Xifaxan |
| Abbott Laboratories | $116.44 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.40 | 2021-2024 | Ofev |
| Amgen INC. | $99.95 | 2025 | Repatha, Otezla |
| Lilly USA, LLC | $83.99 | 2022-2023 | Mounjaro |
| Inspire Medical Systems, INC. | $78.35 | 2024-2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $77.94 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $72.04 | 2022-2025 | Trelegy Ellipta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $62.98 | 2022-2024 | Veozah |
| Amarin Pharma, INC. | $43.66 | 2022 | |
| Lundbeck LLC | $41.87 | 2024-2025 | Rexulti |
| Bausch Health US, LLC | $36.17 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $33.65 | 2022 | |
| Janssen Pharmaceuticals, INC | $33.21 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $20.91 | 2022 | |
| Acerus Pharmaceuticals Corporation | $19.26 | 2022 | |
| Almatica Pharma LLC | $14.97 | 2023 | Sertraline Hcl, Loreev Xr, Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Muratori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.